OraSure Technologies, Inc. (NASDAQ:OSUR)‘s stock had its “buy” rating reaffirmed by Canaccord Genuity in a research report issued to clients and investors on Tuesday. They presently have a $22.00 price objective on the medical instruments supplier’s stock. Canaccord Genuity’s price target points to a potential upside of 0.27% from the stock’s previous close.
Several other equities analysts have also commented on OSUR. Jefferies Group LLC reissued a “buy” rating and issued a $20.00 target price on shares of OraSure Technologies in a report on Tuesday, September 12th. Zacks Investment Research lowered OraSure Technologies from a “buy” rating to a “hold” rating in a report on Tuesday. BidaskClub lowered OraSure Technologies from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Finally, Stephens reissued an “overweight” rating and issued a $19.00 target price (up previously from $14.00) on shares of OraSure Technologies in a report on Tuesday, July 11th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. OraSure Technologies presently has a consensus rating of “Buy” and an average price target of $18.04.
OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.02. The business had revenue of $40.18 million for the quarter, compared to analysts’ expectations of $36.54 million. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same period last year, the firm earned $0.07 earnings per share.
COPYRIGHT VIOLATION NOTICE: This report was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://sportsperspectives.com/2017/09/21/orasure-technologies-inc-osur-rating-reiterated-by-canaccord-genuity.html.
In other OraSure Technologies news, EVP Anthony Zezzo II sold 72,916 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $21.26, for a total transaction of $1,550,194.16. Following the transaction, the executive vice president now owns 218,326 shares of the company’s stock, valued at $4,641,610.76. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Douglas A. Michels sold 290,495 shares of the firm’s stock in a transaction dated Tuesday, June 27th. The stock was sold at an average price of $16.75, for a total value of $4,865,791.25. Following the transaction, the chief executive officer now directly owns 894,012 shares in the company, valued at approximately $14,974,701. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 960,173 shares of company stock worth $18,752,210. Corporate insiders own 6.40% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Federated Investors Inc. PA grew its holdings in shares of OraSure Technologies by 505.6% during the second quarter. Federated Investors Inc. PA now owns 312,595 shares of the medical instruments supplier’s stock worth $5,395,000 after purchasing an additional 260,977 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of OraSure Technologies during the first quarter worth about $594,000. Parametric Portfolio Associates LLC grew its holdings in shares of OraSure Technologies by 103.1% during the first quarter. Parametric Portfolio Associates LLC now owns 178,035 shares of the medical instruments supplier’s stock worth $2,302,000 after purchasing an additional 90,361 shares during the last quarter. Prudential Financial Inc. grew its holdings in shares of OraSure Technologies by 154.4% during the first quarter. Prudential Financial Inc. now owns 562,867 shares of the medical instruments supplier’s stock worth $7,278,000 after purchasing an additional 341,575 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. grew its holdings in shares of OraSure Technologies by 20.7% during the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 20,094 shares of the medical instruments supplier’s stock worth $260,000 after purchasing an additional 3,444 shares during the last quarter. 92.10% of the stock is currently owned by institutional investors.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.